Showing 4301-4310 of 8735 results for "".
- FDA Greenlights NDA for New Impetigo Treatmenthttps://practicaldermatology.com/news/fda-greenlights-nda-for-new-impetigo-treatment/2458449/The U.S. Food and Drug Administration (FDA) has accepted Medimetriks Pharmaceuticals, Inc.'s New Drug Application (NDA) for their novel impetigo treatment, ozenoxacin cream, 1%. Ozenoxacin cream is a non-fluorinated quinolone. The
- Chris Payne Named Chief Marketing Officer at PCA Skinhttps://practicaldermatology.com/news/chris-payne-named-chief-marketing-officer-at-pca-skin/2458454/Chris Payne has been named Chief Marketing Officer at Scottsdale, AZ-based PCA Skin. In this role, Payne will be responsible for leading all marketing and communication initiatives to drive growth of PCA SKIN through both professional and consum
- It's So Far, So Good for BioPharmX's New Acne Drughttps://practicaldermatology.com/news/its-so-far-so-good-for-biopharmxs-new-acne-drug/2458458/BioPharmX Corporation’s novel topical minocycline, BPX-01, reduced facial P. acnes by more than 90 percent after four weeks, new research shows. In the Phase 2a study, a daily 10 mg dose of topical minocycline offered P. acnes r
- Fractional HiFR Helps Fight Signs of Aging on Lower Face/Neckhttps://practicaldermatology.com/news/fractional-hifr-helps-fight-signs-of-aging-on-lower-faceneck/2458469/Fractional high intensity focused radiofrequency (HiFR) is safe and effective in the treatment of mild to moderate laxity of the lower face and neck, new research suggests. The study was selected as Editor’s Choice in the July 2016 issue of
- US FDA Issues Draft Updated Recommendations on Submitting a New 510(k) for Device Modificationshttps://practicaldermatology.com/news/us-fda-issues-draft-of-updated-recommendations-on-submitting-a-new-510k-for-device-modifications/2458471/The U.S. Food and Drug Administration (FDA) issued draft updated recommendations to help manufacturers determine when they are required to notify the FDA about modifications made
- Valeant Dermatology ASPIRE HIGHER Scholarship Program Names Winnershttps://practicaldermatology.com/news/valeant-dermatology-aspire-higher-scholarship-program-names-winners/2458472/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, announced the winners of its ASPIRE HIGHER Scholarship Program. Nine undergraduate and graduate students were selected from a pool of 970 applicants and awarded up to $10,000 each tow
- Dr. Reddy's Sernivo Officially Debuts at NYC Media Eventhttps://practicaldermatology.com/news/dr-reddys-sernivo-officially-debuts-at-nyc-event/2458473/Calling Sernivo (betamethasone dipropionate) Spray 0.05% a ‘trifecta’ for dermatologists who treat mild-to-moderate psoriasis, Josh Zeichner, MD, introduced members of the New York City media to the new spray-on steroid. “It is effe
- BEVL Blasts Off: New Mobile Network Seeks to Connect Aesthetic Proshttps://practicaldermatology.com/news/bevl-blasts-off-new-mobile-network-seeks-to-connect-aesthetic-pros/2458474/Meet BEVL, a new mobile network that connects medical aesthetics professionals. In private beta testing since June, BEVL is now accessible via iOS, Android and th
- Skinbetter scienceTM Debuts with Launch of New Anti-aging Productshttps://practicaldermatology.com/news/skinbetter-sciencetm-debuts-with-launch-of-new-anti-aging-products/2458478/Introducing skinbetter scienceTM ... the brainchild of Jonah Shacknai and several former members of the Medicis leadership team among others. The new line will debut in physician offices nationwide in August 2016. The
- Study: 98% of Head Lice in at Least 42 States Now Resistant to Common OTC Treatmentshttps://practicaldermatology.com/news/98-of-head-lice-in-at-least-42-states-now-resistant-to-common-otc-treatments/2458480/Fully 98 percent of head lice in at least 42 states are resistant to various over-the-counter pyrethrins and pyrethroids including permethrin, which is the active ingredient in popular treatment formulations for pediculosis (Nix® (permethrin 1%), according to a study in t